Conventional Prophylactic Oral Dexamethasone vs Short-course IV Dexamethasone in Paclitaxel Hypersensitivity

Completed · Phase 3

Conditions studied: Hypersensitivity Reactions

In brief

This study is a single center, prospective, randomized, open-label study aimed at determining the most effective means of preventing hypersensitivity reactions in gynecologic oncology patients receiving paclitaxel infusions. The study will therefore provide clinicians with the best ways of preventing paclitaxel hypersensitivity reactions in their patients during treatment. Subjects will be randomized using the block randomization method into one of these three commonly used treatment methods:(1) Conventional method: oral dexamethasone (20 mg), taking 12 hours and 6 hours prior to paclitaxel infusion and intravenous administration of histamine-1 (H1), and a histamine-2 (H2)receptor antagonists administered 30 minutes prior to paclitaxel infusion. (2) Short-course method: intravenous dexamethasone (20 mg), administered concurrently with H1 and H2 antagonists, 30 minutes prior to paclitaxel infusion. (3) Combined method: oral dexamethasone (20 mg), taking 12 hours prior to treatment in addition to intravenous dexamethasone (20 mg), H1 and H2 receptor antagonists administered 30 minutes prior to paclitaxel infusion. The one-way analysis of variance (ANOVA) would be used to determine if there is any significant difference between the different strategies that are used to pre-medicate patients prior to paclitaxel infusion. P-values of less than 0.05 will be considered statistically significant.

Key facts

Study ID: NCT03598426
Run by: Loma Linda University
People needed: 90
Starts: 2018-08-08
Expected to finish: 2025-01-07
Last updated by the study team: 2026-06-09

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

Adult female patients > 18 years of age
Patients of the Loma Linda University Health (LLUH) gynecologic oncology and breast oncology service
Confirmed breast or gynecologic cancer diagnosis of any stage and any gynecologic or breast malignancy
Planned treatment with paclitaxel containing regimen either in the adjuvant setting or for palliation
Planned treatment with paclitaxel should be for 3 or more cycles given as a weekly or every 3 weeks cycle
Paclitaxel should be given as a monotherapy or as part of a combination regimen. If paclitaxel is part of a regimen containing other drugs, the following conditions must be met:
Paclitaxel will be the first chemotherapy regimen to be infused when patient comes in for treatment
Chemotherapy regimen that would be approved for the study are the following:
i. Paclitaxel/ Carboplatin ii. Paclitaxel/Carboplatin/Bevacizumab iii. Paclitaxel/Cisplatin/Bevacizumab iv. Paclitaxel/Bevacizumab v. Paclitaxel/ Ifosfamide vi. Paclitaxel/ Pazopanib
Patients should have no prior exposure to taxanes (this includes: paclitaxel, docetaxel, and protein-bound paclitaxel)
The chemotherapy treatment should be at one of the LLUH Adult Cancer Centers
The patient should be an English or Spanish speaking patient

You may not qualify if…

Patients who are not with the gynecologic or breast oncology service
Patients who are with the gynecologic oncology or breast oncology service but are not receiving paclitaxel either as a monotherapy or in combination with other regimen
Patients who have had prior exposure to taxanes (this includes: paclitaxel, docetaxel, and protein-bound paclitaxel)
Patients who are currently on steroid therapy and it is anticipated that therapy will not be discontinued at least a week prior to start of chemotherapy
Patients with autoimmune diseases, malignancies, and any other co-morbid condition that might require steroid therapy during chemotherapy. This includes, but not limited to:
Crohn's disease
Immune thrombocytopenia
Lupus nephritis
Multiple sclerosis
Primary brain tumors
Multiple Myeloma
Hodgkin's Lymphoma
Patients with uncontrolled diabetes or diabetic or pre-diabetic patients with baseline A1C levels > 8.5
Patients who are allergic to diphenhydramine and/or dexamethasone
Non-English and Non-Spanish speaking patients

Where it is running

Loma Linda University Cancer Center — Loma Linda, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.